• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Viatris Inc.

    3/23/26 4:49:18 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VTRS alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001657568
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Viatris Inc
    SEC File Number
    001-39695
    Address of Issuer
    1000 Mylan Boulevard
    Canonsburg
    PENNSYLVANIA
    15317
    Phone
    724-514-1800
    Name of Person for Whose Account the Securities are To Be Sold
    Paul Campbell
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Stock
    Merrill Lynch
    One Bryant Park
    New York � NY � 10036
    21350283508.28115139292203/23/2026
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common Stock03/03/2026Vesting of Stock AwardsViatris IncCheckbox not checked2135003/03/2026Compensatory Payment

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    03/23/2026

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    Paul Campbell

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $VTRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VTRS

    DatePrice TargetRatingAnalyst
    2/9/2026$18.00Neutral → Buy
    UBS
    1/16/2026$15.00Hold → Buy
    Argus
    12/9/2025$15.00Overweight
    Barclays
    10/15/2025$15.00Buy
    Truist
    6/6/2025$10.00Neutral
    Goldman
    7/19/2024$15.00Buy
    Jefferies
    10/23/2023$13.00 → $9.00Neutral → Underperform
    BofA Securities
    6/23/2023$11.00Equal Weight → Underweight
    Barclays
    More analyst ratings

    $VTRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Viatris upgraded by UBS with a new price target

    UBS upgraded Viatris from Neutral to Buy and set a new price target of $18.00

    2/9/26 6:59:24 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris upgraded by Argus with a new price target

    Argus upgraded Viatris from Hold to Buy and set a new price target of $15.00

    1/16/26 8:41:55 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Viatris with a new price target

    Barclays initiated coverage of Viatris with a rating of Overweight and set a new price target of $15.00

    12/9/25 8:55:06 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Viatris Inc.

    4 - Viatris Inc (0001792044) (Issuer)

    3/10/26 7:03:54 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kilts James M converted options into 24,835 shares, increasing direct ownership by 18% to 161,257 units (SEC Form 4)

    4 - Viatris Inc (0001792044) (Issuer)

    3/10/26 7:03:50 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Viatris Inc.

    4 - Viatris Inc (0001792044) (Issuer)

    3/10/26 7:03:50 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)

    Addresses a Significant Unmet Need in Japan as First and Only Approved Treatment Option for GADPITTSBURGH, March 23, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Effexor® SR 37.5 mg / 75 mg capsules (venlafaxine hydrochloride), a serotonin-noradrenaline reuptake inhibitor (SNRI), for the treatment of adults with generalized anxiety disorder (GAD). Following the MHLW's decision, Effexor® becomes the first and only approved treatment option in Japan for adults living with GAD, addressing a long-standing unmet medical need in mental health and enabling new access to care. Eff

    3/23/26 6:59:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030

    Growing Base Business Evolving Into More Durable Portfolio of Higher-Margin Generics, Value-Added Medicines and Established Brands Expecting Impactful Near-Term Launches, Including Fast-Acting Meloxicam and Low-Dose Estrogen Weekly Patch in the U.S., and Pitolisant and Effexor® for GAD in JapanUnlocking Long-Term Value Through Potential Blockbusters Selatogrel and Cenerimod Strong Cash Flow Generation Enabling Capital Return and Disciplined Business DevelopmentProviding Long-Term Targets for Sustained Growth Through 2030 PITTSBURGH, March 19, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) will host its Investor Event today, where members of the executive leadership team will outline the Com

    3/19/26 8:30:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results

    Reports Fourth-Quarter Total Revenues of $3.7B and Full-Year 2025 Total Revenues of $14.3BMeets or Exceeds 2025 Financial Guidance Across All Key Metrics[1]Returns More Than $1B to Shareholders in 2025; Expects Balanced Capital Allocation Approach for 2026Provides 2026 Financial Guidance; Positioned for Sustainable GrowthAnticipates Regulatory Decisions for Six Product Candidates in 2026 and Multiple Important Pipeline MilestonesCompletes Enterprise-Wide Strategic Review; Expects to Deliver $650M in Total Cost Savings With Reinvestment of up to $250M Over the Next 3 YearsPITTSBURGH, Feb. 26, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced robust financial results for the four

    2/26/26 6:59:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Smith Scott Andrew bought $219,740 worth of shares (22,000 units at $9.99), increasing direct ownership by 8% to 314,807 units (SEC Form 4)

    4 - Viatris Inc (0001792044) (Issuer)

    8/13/25 6:08:30 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Smith Scott Andrew bought $536,262 worth of shares (60,000 units at $8.94), increasing direct ownership by 26% to 292,807 units (SEC Form 4)

    4 - Viatris Inc (0001792044) (Issuer)

    5/14/25 6:00:11 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Korman Harry bought $61,252 worth of shares (4,403 units at $13.91), increasing direct ownership by 6% to 94,960 units (SEC Form 4)

    4 - Viatris Inc (0001792044) (Issuer)

    10/25/24 4:30:03 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    SEC Filings

    View All

    SEC Form 144 filed by Viatris Inc.

    144 - Viatris Inc (0001792044) (Subject)

    3/23/26 4:49:18 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Viatris Inc.

    10-K - Viatris Inc (0001792044) (Filer)

    2/26/26 4:26:46 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits

    8-K - Viatris Inc (0001792044) (Filer)

    2/26/26 7:52:59 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Leadership Updates

    Live Leadership Updates

    View All

    Viatris Appoints Matthew J. Maletta as Chief Legal Officer

    Brian Roman to Leave the Company After More Than 20 Years of Exemplary Service; Will Remain Advisor Through Transition Period  PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) announced today that Matthew J. Maletta has been appointed Chief Legal Officer (CLO), effective February 9, 2026. The appointment follows the transition of the Company's current CLO, Brian Roman, after more than 20 years of exemplary service to Viatris and its predecessor company, Mylan. Roman, who has served in multiple leadership positions and played a key role in supporting the Company's operations, portfolio and growth initiatives, will stay on through April 1, 2026, to ensure a smooth transition

    2/3/26 8:30:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

    PITTSBURGH, Jan. 8, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris' ongoing transformation efforts, this newly combined role is designed to continue to advance the company's culture and connectivity across the globe, while also strengthening the alignment of the organization's internal and external stakeholder communication strategies. Ramsburg is an accomplished leader with more than 25 years of experience building and leading highly effective cross-functional

    1/8/26 9:05:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Appoints Andrew Enrietti as Chief Administrative and Transformation Officer

    PITTSBURGH, Aug. 19, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced the appointment of Andrew Enrietti as Chief Administrative and Transformation Officer. In this newly created role, Enrietti will oversee the company's Human Relations, Business Transformation, Information Technology, Information Security, Global Transportation and Security, and Global Workplaces and Real Estate functions. The consolidation of these areas centralizes leadership of the company's digital, cultural and structural transformation initiatives and is designed to accelerate the company's ongoing strategic evolution.

    8/19/25 9:00:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Financials

    Live finance-specific insights

    View All

    Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results

    Reports Fourth-Quarter Total Revenues of $3.7B and Full-Year 2025 Total Revenues of $14.3BMeets or Exceeds 2025 Financial Guidance Across All Key Metrics[1]Returns More Than $1B to Shareholders in 2025; Expects Balanced Capital Allocation Approach for 2026Provides 2026 Financial Guidance; Positioned for Sustainable GrowthAnticipates Regulatory Decisions for Six Product Candidates in 2026 and Multiple Important Pipeline MilestonesCompletes Enterprise-Wide Strategic Review; Expects to Deliver $650M in Total Cost Savings With Reinvestment of up to $250M Over the Next 3 YearsPITTSBURGH, Feb. 26, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced robust financial results for the four

    2/26/26 6:59:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend

    PITTSBURGH, Feb. 26, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS) today announced that on February 23, 2026, its Board of Directors approved a 2026 dividend policy of 48 cents ($0.48) per share and declared a quarterly dividend of 12 cents ($0.12) for each issued and outstanding share of the Company's common stock. The dividend is payable on March 18, 2026, to shareholders of record as of the close of business on March 9, 2026. This marks the sixth consecutive year the Company has paid a dividend.                 About Viatris Viatris Inc. (NASDAQ:VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of bo

    2/26/26 6:55:00 AM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026

    PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results. Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website. In addition, Viatris will host an Investor Event on March 19, 2026, in New York City. More details regarding the event will be provided during the Co

    2/3/26 4:34:00 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VTRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Viatris Inc.

    SC 13G/A - Viatris Inc (0001792044) (Subject)

    11/12/24 1:41:20 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Viatris Inc. (Amendment)

    SC 13G/A - Viatris Inc (0001792044) (Subject)

    2/13/24 5:17:31 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Viatris Inc.

    SC 13G - Viatris Inc (0001792044) (Subject)

    2/9/24 1:10:51 PM ET
    $VTRS
    Biotechnology: Pharmaceutical Preparations
    Health Care